Compare Medtronic PLC (MDT) vs RELX PLC PLC American Depositary Shares (Each representing One Ordinary Share) (RELX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medtronic PLC vs RELX PLC PLC American Depositary Shares (Each representing One Ordinary Share) — how do they compare? Medtronic PLC trades at $95.03 (market cap $118.97B), while RELX PLC PLC American Depositary Shares (Each representing One Ordinary Share) trades at $36.73 (market cap $63.57B). The key difference: Medtronic PLC is the larger of the two by market cap, and Medtronic PLC pays the higher dividend (3.1%). Which is the better fit depends on your goals.
| MDT | RELX | |
|---|---|---|
Market Cap | $118.97B | $63.57B |
Volume | 24,932,018 | 1,602,093 |
Sector | Health | Industrials |
52-Week High | $105.35 | $46.80 |
52-Week Low | $73.75 | $27.73 |
Typical Hold Time | 63 Days | — |
Enterprise Value | $138.31B | $75.05B |
Dividend Yield | 3.1% | 2.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $94.23, up 2.5% with strong technical momentum near resistance at $95. The stock shows solid fundamentals with consistent earnings beats, 13.93% net margins, and a 49-year dividend growth streak. Recent CPT code approvals for medical devices and raised 2026 guidance signal operational strength. Technical indicators show bullish moving averages but RSI suggests potential overbought conditions near-term.
MDT offers value with 3.2% dividend yield and 7%+ revenue growth, though debt levels have risen to 31.1% of assets. Analyst consensus remains strongly bullish (61% buy ratings) with $97.73 price target. Key risks include execution of the MiniMed separation and medical device competition. The stock presents a balanced opportunity for income and growth investors.
RELX trades at $36.70, up 0.44% with neutral technical signals. The company demonstrates strong profitability with 23.27% net margins and 132.36% ROE, though valuation metrics appear elevated with P/E of 22.21 and P/B of 38.89. Recent earnings show mixed results with Q2 2026 beating expectations while Q4 2025 missed. Analyst sentiment remains positive with 71% buy ratings and consensus price target of $26.00.
The investment case balances strong fundamentals against premium valuation. Growth catalysts include AI-driven product adoption and margin expansion, while risks involve competitive pressures and valuation concerns. With solid cash flow generation and institutional support, RELX offers quality exposure but requires monitoring of valuation multiples and competitive dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →About RELX PLC PLC American Depositary Shares (Each representing One Ordinary Share)
RELX PLC is a UK-based information and analytics company operating across four segments: Risk (fraud prevention and compliance analytics via LexisNexis Risk Solutions), Scientific, Technical & Medical (Elsevier's research and clinical content), Legal (LexisNexis Legal & Professional's research tools), and Exhibitions (RX's trade events). It serves professional, business, and government customers worldwide.
Read more on RELX →
